Showing results (731-740 of 902) with videos related to
Sort By:
Pageof 91
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapyLeonard B Saltz, Lee S Rosen, John L Marshall, et al.Journal of the National Cancer Institute|August 19, 2011
Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803Kimmie Ng, Shuji Ogino, Jeffrey A Meyerhardt, et al.Journal of the National Cancer Institute|November 30, 2014
Aspirin and COX-2 inhibitor use in patients with stage III colon cancerKimmie Ng, Jeffrey A Meyerhardt, Andrew T Chan, et al.Plos One|June 18, 2014
Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance)Michael A Fuchs, Kaori Sato, Donna Niedzwiecki, et al.Gastroenterology|May 27, 2014
CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancerStacey Shiovitz, Monica M Bertagnolli, Lindsay A Renfro, et al.Diseases of the Colon and Rectum|May 17, 2000
Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomographyJ G Guillem, J Puig-La Calle, T Akhurst, et al.IEEE Open Journal of Engineering in Medicine and Biology|November 20, 2024
Optimized Whole-Slide-Image H&E Stain Normalization: A Step Towards Big Data Integration in Digital PathologyJose L Agraz, Carlos Agraz, Andrew A Chen, et al.Genes & Development|January 11, 2007
Rb is critical in a mammalian tissue stem cell populationPamela L Wenzel, Lizhao Wu, Alain de Bruin, et al.JAMA Network Open|September 29, 2022
A Dynamic Clinical Calculator for Estimating Conditional Recurrence-Free Survival After Total Neoadjuvant Therapy for Rectal Cancer and Either Surgery or Watch-and-Wait ManagementMartin R Weiser, Joanne F Chou, Jin K Kim, et al.Cancer Research|January 16, 2019
Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase FusionsEmiliano Cocco, Jamal Benhamida, Sumit Middha, et al.Pageof 91